Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study

OBJECTIVES: To examine the safety of an agonist-type treatment, lisdexamfetamine (LDX), at 250 mg/day among adults with methamphetamine (MA) dependence. DESIGN: A dose-escalating, phase-2, open-label, single-group study of oral LDX at two Australian drug treatment services. SETTING: The study was co...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezard, Nadine, Clifford, Brendan, Dunlop, Adrian, Bruno, Raimondo, Carr, Andrew, Liu, Zhixin, Siefried, Krista J, Lintzeris, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Addiction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137170/
https://www.ncbi.nlm.nih.gov/pubmed/34006547
http://dx.doi.org/10.1136/bmjopen-2020-044696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137170/
https://www.ncbi.nlm.nih.gov/pubmed/34006547
http://dx.doi.org/10.1136/bmjopen-2020-044696

Ejemplares similares